Further to DrugAlert volume 809, HPS Pharmacies wish to advise that all suppliers are continuing to experience a supply interruption for amoxicillin + clavulanic acid 875mg/125mg tablets, as follows:
|Product||ARTG||Estimated return date|
|AmoxyClav Generichealth 875/125||255076||Early March 2023|
|APX-Amoxicillin/Clavulanic Acid||351833||Early December 2022|
|APO-Amoxy/Clav||255080||End November 2022|
|Augmentin Duo Forte||54900||Early December 2022|
|Curam Duo Forte||198109||Mid-December 2022|
An internationally registered brand of amoxicillin + clavulanic acid 875mg/125mg tablets has been approved for supply under Section 19A of the Therapeutic Goods Act 1989.
- Amoxicillin 125mg/5 mL + clavulanic acid 31.25mg/5 mL powder for oral liquid (Curam® Suspension) is now also unavailable with an estimated return date of late February 2023.
- Amoxicillin 400mg/5 mL + clavulanic acid 57 mg/5 mL powder for oral liquid is currently available.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates